Investigating the interplay between FGF-23 and LOXL2 in osteosarcoma may provide new mechanistic insights and identify potential therapeutic targets to inhibit malignant progression and improve clinical outcomes. This evidence concerns the gene LOXL2 and osteosarcoma.